Company profile

HiFiBiO Therapeutics

Privately held: no public share price (Privately held antibody-discovery biotech; most recent raise a $75M Series D, no IPO found. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.fiercebiotech.com/biotech/hifibio-gets-high-five-from-investors-75m-series-d-to-bring-two-programs-into-clinic])

Assets

(2 total)

2Total Assets

0Approved

0Phase 3 / Filed

2Phase 1–2 / Early

1Diseases

Showing 2 of 2 assets

		Target & Modality
HFB200301	Phase 1	TNFR2 (agonist)Small molecule	Non-Small Cell Lung Cancer
HFB200603	Phase 1	BTLASmall molecule	Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.